Our findings open venues to future studies to explore VAMP8/DHX9/p65 axis as biomarkers and therapeutic targets in NPC, with implications for understanding the broader genetic and molecular mechanisms of NPC pathogenesis. This evidence concerns the gene DHX9 and nasopharyngeal carcinoma.